Urine analysis offers certain noteworthy advantages compared to blood, including truly non-invasive sampling, opportunity for more frequent collection, and larger obtainable volumes. However, analysis of clinically-relevant urine proteins or protein modifications has been incredibly challenging.
Why choose Tymora Analytical urine proteomics/PTMs?
- Our recently published manuscript in PNAS demonstrates for the first time the feasibility to identify thousands of phosphoproteins in plasma extracellular vesicles (EVs).
- We have now also developed the ability to identify hundreds of phosphoproteins from urine samples (manuscript in preparation).
- On average, using 10mL of urine as the starting material, we can routinely identify more than 3,200 unique phosphopeptides, representing > 1,200 unique phosphoproteins.
- The identification numbers are significantly better than anything previously reported (highest previously reported number – 14 urine phosphoproteins).
- The analysis is based on selective profiling of EVs secreted into urine by all cells, with diseased cells/tumors producing unique EVs with specialized cargo.
- To effectively capture urinary EVs, we utilize our in-house developed patent-pending EVtrap method that allows extraction of >95% of all EVs with very low contamination level.
- Our approach to date is the first and only method to successfully demonstrate the feasibility of developing urine-derived EV phosphoproteins for disease profiling.